How to Antiproliferative Agents?

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

Hiro

145 results about "Antiproliferative Agents" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

The maintenance agents are generally 4 classes of drugs. Calcineurin Inhibitors: Tacrolimus and Cyclosporine. Antiproliferative agents: Mycophenolate Mofetil, Mycophenolate Sodium and Azathioprine. mTOR inhibitor: Sirolimus. Steroids: Prednisone.

Multi-Functional Small Molecules as Anti-Proliferative Agents

InactiveUS20080221132A1High activityBiocideNervous disorderHistone deacetylaseAntiproliferative Agents

The present invention relates to the compositions, methods, and applications of a novel approach to selective inhibition of several cellular or molecular targets with a single small molecule. More specifically, the present invention relates to multi-functional small molecules wherein one functionality is capable of inhibiting histone deacetylases (HDAC) and the other functionality is capable of inhibiting a different cellular or molecular pathway involved in aberrant cell proliferation, differentiation or survival.

Multi-Functional Small Molecules as Anti-Proliferative Agents

View all

Owner:CURIS INC

Medical devices to treat or inhibit restenosis

InactiveUS20050137683A1StentsBlood vesselsAtrasentanPercent Diameter Stenosis

Implantable medical devices having anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of certain antiproliferative agents, particularly a certain endothelin receptor inhibitor, are disclosed. The anti-restenotic endothelin receptor inhibitor is atrasentan, and pharmaceutically acceptable derivatives thereof. The anti-restenotic medical devices include stents, catheters, micro-particles, probes and vascular grafts. Intravascular stents are preferred medical devices. The medical devices can be coated using any method known in the art including compounding the endothelin receptor inhibitor with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-endothelin receptor inhibitor blends are disclosed. Additionally, medical devices having a coating comprising at least one endothelin receptor inhibitor in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the anti-restenotic implantable devices are also disclosed.

Medical devices to treat or inhibit restenosis

View all

Owner:MEDTRONIC VASCULAR INC

Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints

ActiveUS20050025765A1Extended half-lifeEliminate side effectsOrganic active ingredientsPeptide/protein ingredientsWhite blood cellOrthopedic department

The present invention relates to trans-capsularly administering into a diseased joint a high specificity antagonist selected from the group consisting of: i) an inhibitor of a pro-inflammatory interleukin; ii) an inhibitor of TNF-α synthesis; iii) an inhibitor of membrane-bound TNF-α; iv) an inhibitor of a natural receptor of TNF-α; v) an inhibitor of NO synthase,

- vi) an inhibitor of PLA₂enzyme; vii) an anti-proliferative agent; viii) an anti-oxidant; ix) an apoptosis inhibitor selected from the group consisting of EPO mimetic peptides, EPO mimetibodies, IGF-I, IGF-II, and caspase inhibitors, and x) an inhibitor of MMPs; and xi) an inhibitor of p38 kinase.

Owner:DEPUY SYNTHES PROD INC

Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative,and inflammatory disorders

InactiveUS20060135549A1Useful in treatmentBiocideNervous disorderAntiproliferative AgentsNeurological disorder

The present invention provides compounds of the following structure, wherein R₁, R₂, R₄, R_4′, R₆, R₇, and R₁₅are defined above:

These compounds are useful in treating neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders. The compounds are therefore useful as neuroprotective and neuroregenerative, anti-proliferative, and anti-inflammatory agents.

Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative,and inflammatory disorders

View all

Owner:WYETH LLC

Method for treating abnormal cell growth

InactiveUS20050272755A1Ease of detectabilityEasy to prepareBiocideAnimal repellantsAbnormal tissue growthMetabolite

The present Invention relates to a method of treating abnormal cell growth in a subject, comprising administering to said subject having abnormal cell growth: (a) a compound selected from the group consisting of a camptothecin, a camptothecin derivative, or a pharmaceutically acceptable salt, solvate or prodrug of said compounds; (b) a pyrimidine derivative or a pharmaceutically acceptable salt, solvate or prodrug of said pyrimidine derivative; and (c) an anti-tumor agent selected from the group consisting of antiproliferative agents, kinase inhibitors, angiogenesis inhibitors, growth factor inhibitors, cox-I inhibitors, cox-II inhibitors, mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, radiation, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, anti-androgens and combinations thereof.

Method for treating abnormal cell growth

View all

Owner:PFIZER INC

Medical devices to treat or inhibit restenosis

InactiveUS20050152940A1StentsSurgeryPercent Diameter StenosisAntiproliferative Agents

Implantable medical devices having anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of certain antiproliferative agents, particularly a certain KSP inhibitor, are disclosed. The anti-restenotic KSP inhibitor is CK-0238273, and pharmaceutically acceptable derivatives thereof. The anti-restenotic medical devices include stents, catheters, micro-particles, probes and vascular grafts. Intravascular stents are preferred medical devices. The medical devices can be coated using any method known in the art including compounding the KSP inhibitor with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-KSP inhibitor blends are disclosed. Additionally, medical devices having a coating comprising at least one KSP inhibitor in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the anti-restenotic implantable devices are also disclosed.

View all

Owner:MEDTRONIC VASCULAR INC

Drug eluting lead systems

InactiveUS20080195227A1Spinal electrodesHead electrodesAntiepileptic AgentsActive agent

Medical electrical lead systems and related methods are described. The lead systems may be configured to be at least partially implanted in neural tissue of a subject, such as a brain of a subject. Some variations of the lead systems may comprise a lead body, an electrode connected to the lead body, and a bioactive agent. The electrode and / or lead body may comprise a substrate, and the bioactive agent may be supported by the substrate (e.g., by a substantial portion of the area of the substrate). Examples of bioactive agents that may be used in the lead system include antiproliferative agents, bactericidal agents, bacteriostatic agents, antiepileptic agents, and / or antifungal agents. Methods described herein may comprise coating a lead body and / or an electrode of a medical electrical lead system with at least one bioactive agent, where the lead body and the electrode are connected to each other.

View all

Owner:NEUROPACE

2-Desmethyl ansamycin compounds

ActiveUS20050026894A1Reduce potential side effectsBiocideOrganic chemistryAntiproliferative AgentsMedicinal chemistry

2-Desmethyl ansamycins having a structure according to formula I, where R¹, R², R³, R⁴, R⁵and R⁶are as defined herein, and other 2-desmethyl ansamycins are useful as antiproliferative agents.

View all

Owner:KOSAN BIOSCI

Combinations of drugs for the treatment of neoplasms

InactiveUS20050137185A1BiocideNervous disorderMISCELLANEOUS TUMORSNeoplasm

The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient chlorpromazine or a chlorpromazine analog and an antiproliferative agent simultaneously or within 14 days of each other in amounts sufficient to treat the patient.

Combinations of drugs for the treatment of neoplasms

View all

Owner:COMBINATORX

Pharmaceutical composition for treating hyperplasia diseases

ActiveCN101675930AGood treatment effectOrganic active ingredientsOrganic chemistryDiseaseAntiproliferative Agents

The invention relates to a pharmaceutical composition for treating hyperplasia diseases such as tumors, Which contains a compound of a formula I or its pharmaceutically acceptable salts, and at leastan antiproliferative agent. The pharmaceutical composition has a cooperative synergism.

View all

Owner:JIANGSU HENGRUI MEDICINE CO LTD +1

Nucleoside phosphonate derivatives

InactiveUS20090274686A1BiocideSugar derivativesAntiproliferative AgentsBiochemical Process

The present invention discloses compounds of formula (I) or (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral/anti-proliferative compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral infection in a subject in need of such therapy with said compounds.

View all

Owner:ENANTA PHARM INC

Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof

InactiveUS8808702B2BiocideOrganic compound preparationAntibody conjugateAntiproliferative Agents

Compounds useful as antiproliferative agents according to formula (I): wherein Ar1, Ar2, Ar3, m and n are as defined herein, salts, antibody conjugates, pharmaceutical compositions, methods of treatment, and synthetic methods are provided.

Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof

View all

Owner:TEMPLE UNIVERSITY

Supplemented and unsupplemented tissue sealants, methods of their production and use

InactiveUSRE39298E1Decreasing thrombogenicityLow antigenicityOrganic active ingredientsPowder deliveryTissue sealantVascular dilatation

This invention provides methods for the localized delivery of supplemented tissue sealants, wherein the supplemented tissue sealants comprise at least one composition which is selected from one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, antiproliferatives, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Further provided are methods of using the site-specific supplemented tissue sealants, including preparation of a biomaterial.

Supplemented and unsupplemented tissue sealants, methods of their production and use

View all

Owner:AMERICAN NAT RED CROSS

Integrin interaction inhibitors for the treatment of cancer

ActiveUS8853149B2Prevent and delay onsetPeptide/protein ingredientsPeptidesAntiproliferative AgentsIntegrin

Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.

Integrin interaction inhibitors for the treatment of cancer

View all

Owner:H LEE MOFFITT CANCER CENT & RES INST INC +1

Combinations of drugs for the treatment of neoplasms

InactiveUS20050054708A1Slow spreadRelieve symptomsBiocideAnimal repellantsPentamidineNeoplasm

The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient pentamidine or a pentamidine analog and an antiproliferative agent simultaneously or within 14 days of each other in amounts sufficient to treat the patient.

View all

Owner:COMBINATORX

Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof

ActiveUS8058313B2BiocideNervous disorderAcyl groupAntiproliferative Agents

α,β-Unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides of Formula I:wherein R1, R2, M1, M2, L, E1, E2, Q1, Q2 and n are as defined herein, are useful as anti-angiogenesis agents, as agents for treatment of age related senile dementia, and as antiproliferative agents including, for example, as anticancer agents.

Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof

View all

Owner:TEMPLE UNIVERSITY

Artificial crystal with antiproliferous medicine coating for preventing and treating after-cataract forming

InactiveCN101053680AGrowth inhibitionGood treatment effectIntraocular lensTreatment effectAntiproliferative Agents

An artificial lens having stents coated with antiproliferative agents for prevention and treatment of the posterior capsule opacification, the invention relates to an artificial lens having stents coating for solving problems of time of present artificial lens loaded with medicine acting on cornea is short. The artificial lens having stents coated with antiproliferative agents for prevention and treatment of the posterior capsule opacification is prepared by ordinary artificial lens and coating with antiproliferative agents, wherein the coating with antiproliferative agents adheres on surface of ordinary artificial lens, thickness of the coating is 3 to 20 mum. The invention adopts macomolecule coating material to coat antiproliferative agents on artificial lens, slowly releases agents in capsules and ambitus cells, represses generation of lens epithelial cell, prevents and cures formation of the posterior capsule opacification. The agents of the invention act on cornea long time, capable of releasing effectively 90 to 120 days, have good therapeutic, patients use the artificial lens of the invention, formation rate of the posterior capsule opacification reduced greatly from more than 60% to 10% and without untoward reaction.

Artificial crystal with antiproliferous medicine coating for preventing and treating after-cataract forming

View all

Owner:刘红玲

Bifunctional heterocyclic compounds and methods of making and using same

ActiveUS7091196B2Antibacterial agentsBiocideAntiparasite agentBifunctional

The invention provides a family of compounds useful as anti-infective agents and / or anti-proliferative agents, for example, chemotherapeutic agents, anti-fungal agents, anti-bacterial agents, anti-parasitic agents, anti-viral agents, and / or anti-inflammatory agents, and / or prokinetic (gastrointestinal modulatory) agents, having the formula:or pharmaceutically acceptable salts, esters, or prodrugs thereof.

Bifunctional heterocyclic compounds and methods of making and using same

View all

Owner:BIOVERSYS AG

Novel pyrimidine derivatives 698

InactiveUS20080242663A1Useful in therapyOrganic active ingredientsOrganic chemistryDiseaseMedicine

The invention concerns compounds of Formula I, or a pharmaceutically acceptable salt thereof,

where R¹, n, R², R³, and R⁴are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4 kinases.

View all

Owner:ASTRAZENECA AB

Drug eluting lead systems

InactiveUS7844345B2Spinal electrodesHead electrodesAntiepileptic AgentsActive agent

View all

Owner:NEUROPACE

4-anilino quinazoline derivatives as antiproliferative agents

InactiveCN101003515AOrganic active ingredientsOrganic chemistryTyrosineAntiproliferative Agents

The invention concerns quinazoline derivatives of Formula (I) wherein each of Q<1>, Z, R<1> and Q<2> have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.